Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation

Sandeep Soni; Micah Skeens; Amanda M. Termuhlen; Rajinder P.S. Bajwa; Thomas G. Gross; Vinita Pai

doi:10.1002/pbc.24126

Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation

Sandeep Soni, Micah Skeens, Amanda M. Termuhlen, Rajinder P.S. Bajwa, Thomas G. Gross, Vinita Pai

Research output: Contribution to journal › Article › peer-review

35 Scopus citations

Abstract

Anti-seizure prophylaxis is routinely utilized during busulfan administration for HSCT. We evaluated the feasibility and efficacy of levetiracetam in children undergoing HSCT. A total of 28 children and young adults received levetiracetam during HSCT and the outcomes and costs were compared to a historical, but similar cohort of 25 patients who had received fosphenytoin. Levetiracetam was well tolerated and was efficacious in preventing seizures. Cost of drug, administration, and monitoring were also similar among the two groups. Due to non-induction of the hepatic cytochrome P450 enzymes, levetiracetam may lead to better dose assurance of busulfan in targeted dose regimens for HSCT. Pediatr Blood Cancer 2012;59:762-764.

Original language	English (US)
Pages (from-to)	762-764
Number of pages	3
Journal	Pediatric Blood and Cancer
Volume	59
Issue number	4
DOIs	https://doi.org/10.1002/pbc.24126
State	Published - Oct 2012
Externally published	Yes

Keywords

BMT
Busulfan
Levetiracetam
Seizures

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1002/pbc.24126

OpenUrl availability

Full text

Cite this

@article{d64a12cb275c49a7b2e30986d1c84bb9,

title = "Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation",

abstract = "Anti-seizure prophylaxis is routinely utilized during busulfan administration for HSCT. We evaluated the feasibility and efficacy of levetiracetam in children undergoing HSCT. A total of 28 children and young adults received levetiracetam during HSCT and the outcomes and costs were compared to a historical, but similar cohort of 25 patients who had received fosphenytoin. Levetiracetam was well tolerated and was efficacious in preventing seizures. Cost of drug, administration, and monitoring were also similar among the two groups. Due to non-induction of the hepatic cytochrome P450 enzymes, levetiracetam may lead to better dose assurance of busulfan in targeted dose regimens for HSCT. Pediatr Blood Cancer 2012;59:762-764.",

keywords = "BMT, Busulfan, Levetiracetam, Seizures",

author = "Sandeep Soni and Micah Skeens and Termuhlen, {Amanda M.} and Bajwa, {Rajinder P.S.} and Gross, {Thomas G.} and Vinita Pai",

year = "2012",

month = oct,

doi = "10.1002/pbc.24126",

language = "English (US)",

volume = "59",

pages = "762--764",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "4",

}

TY - JOUR

T1 - Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation

AU - Soni, Sandeep

AU - Skeens, Micah

AU - Termuhlen, Amanda M.

AU - Bajwa, Rajinder P.S.

AU - Gross, Thomas G.

AU - Pai, Vinita

PY - 2012/10

Y1 - 2012/10

N2 - Anti-seizure prophylaxis is routinely utilized during busulfan administration for HSCT. We evaluated the feasibility and efficacy of levetiracetam in children undergoing HSCT. A total of 28 children and young adults received levetiracetam during HSCT and the outcomes and costs were compared to a historical, but similar cohort of 25 patients who had received fosphenytoin. Levetiracetam was well tolerated and was efficacious in preventing seizures. Cost of drug, administration, and monitoring were also similar among the two groups. Due to non-induction of the hepatic cytochrome P450 enzymes, levetiracetam may lead to better dose assurance of busulfan in targeted dose regimens for HSCT. Pediatr Blood Cancer 2012;59:762-764.

AB - Anti-seizure prophylaxis is routinely utilized during busulfan administration for HSCT. We evaluated the feasibility and efficacy of levetiracetam in children undergoing HSCT. A total of 28 children and young adults received levetiracetam during HSCT and the outcomes and costs were compared to a historical, but similar cohort of 25 patients who had received fosphenytoin. Levetiracetam was well tolerated and was efficacious in preventing seizures. Cost of drug, administration, and monitoring were also similar among the two groups. Due to non-induction of the hepatic cytochrome P450 enzymes, levetiracetam may lead to better dose assurance of busulfan in targeted dose regimens for HSCT. Pediatr Blood Cancer 2012;59:762-764.

KW - BMT

KW - Busulfan

KW - Levetiracetam

KW - Seizures

UR - http://www.scopus.com/inward/record.url?scp=84864923619&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864923619&partnerID=8YFLogxK

U2 - 10.1002/pbc.24126

DO - 10.1002/pbc.24126

M3 - Article

C2 - 22378696

AN - SCOPUS:84864923619

SN - 1545-5009

VL - 59

SP - 762

EP - 764

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 4

ER -

Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation

Abstract

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this